Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSV + influenza mRNA therapeutic
- Development stage
- Unknown
- Lead developer
- Arnav Biotech
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
RSV + influenza mRNA therapeutic is an mRNA-based combination vaccine candidate being developed by Arnav Biotech for the prevention of Respiratory Syncytial Virus (RSV) and Influenza infections. The therapeutic utilizes messenger RNA technology to encode viral antigens from both RSV and Influenza viruses, aiming to elicit a dual protective immune response. As of early development reports, the program is in the pre-clinical phase, leveraging Arnav Biotech's proprietary mRNA manufacturing and research capabilities to address two major respiratory pathogens with a single intervention.
- Other names
- RSV+Influenza mRNA therapeutic
02
Targets
Flu (Influenza surface proteins)
Beyond the preview
Go deeper on RSV + influenza mRNA therapeutic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV + influenza mRNA therapeutic.